Asymmetric Dimethylarginin (ADMA) as a Marker of Endothelial Dysfunction in Primary Aldosteronism

Authors Information
Article Notes and Dates
To Cite : Matrozova J, Vasilev V, Vandeva S, Elenkova A, Kirilov G, et al. Asymmetric Dimethylarginin (ADMA) as a Marker of Endothelial Dysfunction in Primary Aldosteronism, Int J Endocrinol Metab. 2016 ;14(4):e30324. doi: 10.5812/ijem.30324.
Copyright: Copyright © 2016, International Journal of Endocrinology and Metabolism. .
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. Ganguly A. Primary aldosteronism. N Engl J Med. 1998; 339(25): 1828-34[DOI][PubMed]
  • 2. Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, Mosso L, et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab. 2004; 89(3): 1045-50[DOI][PubMed]
  • 3. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005; 45(8): 1243-8[DOI][PubMed]
  • 4. Born-Frontsberg E, Reincke M, Rump LC, Hahner S, Diederich S, Lorenz R, et al. Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn's Registry. J Clin Endocrinol Metab. 2009; 94(4): 1125-30[DOI][PubMed]
  • 5. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation. 2000; 101(16): 1899-906[PubMed]
  • 6. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation. 2001; 104(22): 2673-8[PubMed]
  • 7. Vallance P, Leone A, Calver A, Collier J, Moncada S. Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol. 1992; 20 Suppl 12: 60-2[PubMed]
  • 8. Valkonen VP, Paiva H, Salonen JT, Lakka TA, Lehtimaki T, Laakso J, et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet. 2001; 358(9299): 2127-8[DOI][PubMed]
  • 9. Meinitzer A, Seelhorst U, Wellnitz B, Halwachs-Baumann G, Boehm BO, Winkelmann BR, et al. Asymmetrical dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (the Ludwigshafen Risk and Cardiovascular Health study). Clin Chem. 2007; 53(2): 273-83[DOI][PubMed]
  • 10. Perticone F, Sciacqua A, Maio R, Perticone M, Maas R, Boger RH, et al. Asymmetric dimethylarginine, L-arginine, and endothelial dysfunction in essential hypertension. J Am Coll Cardiol. 2005; 46(3): 518-23[DOI][PubMed]
  • 11. Abbasi F, Asagmi T, Cooke JP, Lamendola C, McLaughlin T, Reaven GM, et al. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol. 2001; 88(10): 1201-3[PubMed]
  • 12. Boger RH, Bode-Boger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation. 1998; 98(18): 1842-7[PubMed]
  • 13. Krempl TK, Maas R, Sydow K, Meinertz T, Boger RH, Kahler J. Elevation of asymmetric dimethylarginine in patients with unstable angina and recurrent cardiovascular events. Eur Heart J. 2005; 26(18): 1846-51[DOI][PubMed]
  • 14. Rossi E, Regolisti G, Negro A, Sani C, Davoli S, Perazzoli F. High prevalence of primary aldosteronism using postcaptopril plasma aldosterone to renin ratio as a screening test among Italian hypertensives. Am J Hypertens. 2002; 15(10 Pt 1): 896-902[PubMed]
  • 15. Matrozova J, Zacharieva S, Kirilov G, Boyanov M. Prevalence of primary aldosteronism among Bulgarian hypertensive patients. Central European J Medi. 2010; 5(3): 399-405[DOI]
  • 16. Giannotti G, Landmesser U. Endothelial dysfunction as an early sign of atherosclerosis. Herz. 2007; 32(7): 568-72[DOI][PubMed]
  • 17. Erzen B, Sabovic M, Sebestjen M, Poredos P. Endothelial dysfunction in post-myocardial infarction patients with various expressions of risk factors. Endothelium. 2007; 14(4-5): 185-91[DOI][PubMed]
  • 18. Ferrari R, Bachetti T, Agnoletti L, Comini L, Curello S. Endothelial function and dysfunction in heart failure. Eur Heart J. 1998; 19 Suppl G: 41-7[PubMed]
  • 19. Jansson PA. Endothelial dysfunction in insulin resistance and type 2 diabetes. J Intern Med. 2007; 262(2): 173-83[DOI][PubMed]
  • 20. Pasqualini L, Marchesi S, Vaudo G, Siepi D, Angeli F, Paris L, et al. Association between endothelial dysfunction and major cardiovascular events in peripheral arterial disease. Vasa. 2003; 32(3): 139-43[DOI][PubMed]
  • 21. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet. 1992; 339(8793): 572-5[PubMed]
  • 22. Borgeraas H, Hertel JK, Svingen GF, Pedersen ER, Seifert R, Nygard O, et al. Association between Body Mass Index, Asymmetric Dimethylarginine and Risk of Cardiovascular Events and Mortality in Norwegian Patients with Suspected Stable Angina Pectoris. PLoS One. 2016; 11(3): 152029[DOI][PubMed]
  • 23. El Assar M, Angulo J, Santos-Ruiz M, Ruiz de Adana JC, Pindado ML, Sanchez-Ferrer A, et al. Asymmetric dimethylarginine (ADMA) elevation and arginase up-regulation contribute to endothelial dysfunction related to insulin resistance in rats and morbidly obese humans. J Physiol. 2016; 594(11): 3045-60[DOI][PubMed]
  • 24. Willeit P, Freitag DF, Laukkanen JA, Chowdhury S, Gobin R, Mayr M, et al. Asymmetric dimethylarginine and cardiovascular risk: systematic review and meta-analysis of 22 prospective studies. J Am Heart Assoc. 2015; 4(6): 1833[DOI][PubMed]
  • 25. Ikeda U, Kanbe T, Nakayama I, Kawahara Y, Yokoyama M, Shimada K. Aldosterone inhibits nitric oxide synthesis in rat vascular smooth muscle cells induced by interleukin-1 beta. Eur J Pharmacol. 1995; 290(2): 69-73[PubMed]
  • 26. Nishizaka MK, Zaman MA, Green SA, Renfroe KY, Calhoun DA. Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism. Circulation. 2004; 109(23): 2857-61[DOI][PubMed]
  • 27. Taddei S, Virdis A, Mattei P, Salvetti A. Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension. 1993; 21(6 Pt 2): 929-33[PubMed]
  • 28. Osanai T, Saitoh M, Sasaki S, Tomita H, Matsunaga T, Okumura K. Effect of shear stress on asymmetric dimethylarginine release from vascular endothelial cells. Hypertension. 2003; 42(5): 985-90[DOI][PubMed]
  • 29. Achan V, Broadhead M, Malaki M, Whitley G, Leiper J, MacAllister R, et al. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol. 2003; 23(8): 1455-9[DOI][PubMed]
  • 30. Vasilev V, Matrozova J, Elenkova A, Vandeva S, Kirilov G, Zacharieva S. Asymmetric dimethylarginine (ADMA) and soluble vascular cell adhesion molecule 1(sVCAM-1) as circulating markers for endothelial dysfunction in patients with pheochromocytoma. Exp Clin Endocrinol Diabetes. 2013; 121(9): 551-5[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiaion Alert via Google Reader

Cited By:

International Journal of Endocrinology and Metabolism accepts terms & conditions of:

International Committee of Medical Journal Editors (ICMJE) Citedby Linking DOI enabled Crossref iThenticate COPE Cross Check